(Q68126733)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1586984%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

title

A randomised phase II study of carmustine alone or in combination with tumour necrosis factor in patients with advanced melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1586984%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

author name string

A. L. Jones

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1586984

11 October 2022

M. E. O'Brien

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1586984

11 October 2022

A. Lorentzos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1586984

11 October 2022

C. Viner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1586984

11 October 2022

A. Hanrahan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1586984

11 October 2022

J. Moore

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1586984

11 October 2022

J. L. Millar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1586984

11 October 2022

M. E. Gore

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1586984

11 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1586984

11 October 2022

publication date

1 January 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1586984%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

22 September 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1586984%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1586984%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1586984%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

page(s)

73-76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1586984%20AND%20SRC:MED&resulttype=core&format=json

Cachectin: more than a tumor necrosis factor

22 September 2019

cites work

1 reference

12 December 2020

DTIC (NSC-45388) in malignant melanoma: a perspective

1 reference

12 December 2020

Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts

1 reference

12 December 2020

Tumour necrosis factor: clinical relevance.

1 reference

12 December 2020

Effect of tumour necrosis factor on cultured human melanoma cells

1 reference

12 December 2020

Nitrosoureas in the management of disseminated malignant melanoma

1 reference

12 December 2020

Systemic chemotherapy for metastatic melanoma

1 reference

12 December 2020

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit

1 reference

12 December 2020

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

12 December 2020

Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo

1 reference

12 December 2020

Tumour necrosis factor in man: clinical and biological observations

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses

1 reference

12 December 2020

Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II.

1 reference

12 December 2020

Recombinant tumor necrosis factor: species specificity for a variety of human and murine transformed cell lines

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00686489

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1586984%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference